Brinker Capital Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Brinker Capital Investments’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,739	Closed	-$1.65M	–	1997
2024 Q4	$1.65M	Sell	19,739 -2,695	-12%	-$221K	0.02%	791
2024 Q3	$1.64M	Sell	22,434 -1,389	-6%	-$104K	0.02%	788
2024 Q2	$1.63M	Sell	23,823 -789	-3%	-$54.7K	0.02%	750
2024 Q1	$1.7M	Sell	24,612 -493	-2%	-$33.9K	0.02%	735
2023 Q4	$1.8M	Sell	25,105 -2,193	-8%	-$126K	0.02%	683
2023 Q3	$1.42M	Sell	27,298 -1,061	-4%	-$61.8K	0.02%	760
2023 Q2	$1.8M	Buy	+28,359	New	+$1.77M	0.02%	708
2023 Q1	–	Sell	-27,689	Closed	-$1.47M	–	1664
2022 Q4	$1.47M	Buy	27,689 +923	+3%	+$46.3K	0.03%	597
2022 Q3	$1.25M	Buy	+26,766	New	+$1.4M	0.03%	621

Other funds holding ITCI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Brinker Capital Investments's ITCI Position: Q1 2025 in Review

Brinker Capital Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 19,739 shares — an estimated $1.65M sold.

Brinker Capital Investments first reported a position in ITCI in Q3 2022 and held it in 9 quarters. The position peaked at $1.8M in Q4 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

Brinker Capital Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
Brinker Capital Investments sold 19,739 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $1.65M.
Brinker Capital Investments first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 9 quarters.
Brinker Capital Investments's Intra-Cellular Therapies Inc. position peaked at $1.8M in Q4 2023.
395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Brinker Capital Investments's 13F filing for Q1 2025, filed 1 Aug 2025.